跳至主要内容
临床试验/NCT02972177
NCT02972177Unknown不适用

Clinical Study of Navigation Bronchoscopy Guided Ablation for the Treatment of Peripheral Lung Tumor

Shanghai Chest Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年2月7日最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
Local control rate

研究概览

简要总结

The objective of the study was to evaluate the efficacy and safety of navigation bronchoscopy guided transbronchial ablation for the treatment of inoperable peripheral lung tumor.

详细描述

The study is aimed to evaluate the efficacy and safety of navigation bronchoscopy guided transbronchial ablation for treating inoperable malignant lung tumor. The study is designed as a single-center prospective trial. The participating centers are Department of pulmonary medicine and endoscopy, Shanghai Chest Hospital,Shanghai Jiao Tong University, China. Patients are divided into two groups, including radiofrequency ablation group and microwave ablation group. Sixty patients are expected to be enrolled into the study with 30 patients in each group.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients older than 18 year-old.
  • Patients meeting one of the following criteria: 1) patients discovered with peripheral lung lesions that have demonstrated to be lung cancer by pathology with the clinical stage no later than IIA. 2) recurrent or progressive single lesion or solitary intrapulmonary metastasis after surgery, radiotherapy, chemotherapy or other treatment.3) multiple primary lung cancer with the number of tumors no more than 5 and no metastasis. 4) pulmonary metastases with effective treatment of primary disease, the number of metastases no more than 5 and no other metastasis.
  • Chest CT shows the length-diameter of the tumor is more than 8mm and no more than 50mm.
  • Patients are unsuitable for surgery assessed by multidisciplinary team and agree to the primary treatment of ablation.
  • Patients have good compliance and sign the informed consent.

排除标准

  • Patients cannot receive bronchoscopy for the severe cardiopulmonary dysfunction and other indications.
  • Patients have contraindications of general anesthesia.
  • Chest CT or bronchoscopy shows that guided and treatment instruments cannot reach the peripheral lung lesion.
  • There are large blood vessels or important structures adjacent to peripheral lung lesion.
  • Researchers consider the patient do not fit for the study due to other reasons.

结局指标

主要结局

Local control rate

时间窗: Three months after ablation

Local control rate was defined as the proportion of the complete ablation and incomplete ablation of the tumor.

次要结局

  • Progression-free survival (PFS)(From the time of treatment to the time of disease progression or death, assessed up to 1 year)
  • Overall survival(OS)(From the time of treatment to the time of the patient death, assessed up to 3 years)
  • Cancer-specific survival(From the time of treatment to the time of the patient death, assessed up to 3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jiayuan Sun

Director, Department of Endoscopy

Shanghai Chest Hospital

研究点 (1)

Loading locations...

相似试验